What is Crossject?
Crossject Société Anonyme is at the forefront of revolutionizing drug delivery with its proprietary ZENEO needle-free injection system. This technology aims to enhance patient compliance and safety by enabling self-administration of critical medications for various conditions. The company's product pipeline is robust, featuring potential treatments for epileptic seizures (Midazolam), opioid overdose (Naloxone), severe asthma crises (Terbutaline), anaphylactic shock (Epinephrine), migraines (Sumatriptan), acute adrenal crisis (Hydrocortisone), and rheumatoid arthritis (Methotrexate). The company's focus on developing user-friendly, needle-free alternatives positions it as a key player in the evolving pharmaceutical and medical device landscape.
How much funding has Crossject raised?
Crossject has raised a total of $60.4M across 6 funding rounds:
Debt
$12M
Unspecified
$7.6M
Multiple Rounds
$23.5M
Stock/Share Issuance
$17.3M
Debt (2020): $12M, investors not publicly disclosed
Unspecified (2024): $7.6M led by Agence nationale de la recherche ANR
Stock/Share Issuance (2025): $6.4M, investors not publicly disclosed
Other Financing Round (2025): $11.3M featuring Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $5.8M backed by Vatel Capital
Stock/Share Issuance (2026): $17.3M, investors not publicly disclosed
Key Investors in Crossject
Agence nationale de la recherche ANR
The ANR is the French national agency responsible for funding project-based research across various scientific disciplines, supporting initiatives for sustainable development and international collaborations.
Vatel Capital
Vatel Capital provides financial planning services in France, assisting clients with money management, tax reduction strategies, and investment planning to achieve better returns and personalized financial outcomes.
Biomedical Advanced Research and Development Authority (BARDA
BARDA enhances public health security by facilitating the development of innovative medical countermeasures for threats and public health emergencies, partnering with innovators from preclinical stages to FDA approval.
What's next for Crossject?
With the recent infusion of $17.3M in a major strategic investment, Crossject is poised for significant expansion and market penetration. The enterprise-level funding context suggests the company is moving towards a scaling phase, likely focusing on scaling manufacturing capabilities, expanding its clinical trial pipeline, and initiating broader commercial launch strategies. The chronological progression of its funding rounds, from earlier debt financing to more recent equity and unspecified rounds, indicates a steady build-up of resources to support its ambitious growth objectives. Future developments will likely center on regulatory approvals and market adoption of its needle-free injection systems across its targeted therapeutic areas.
See full Crossject company page
